Adverse effects of drugs in the treatment of viral hepatitis
- 30 April 2010
- journal article
- review article
- Published by Elsevier in Best Practice & Research Clinical Gastroenterology
- Vol. 24 (2), 183-192
- https://doi.org/10.1016/j.bpg.2009.10.012
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients #Hepatology, 2009
- Interferon-α2b–induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytesBlood, 2008
- A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatmentJournal of Viral Hepatitis, 2008
- Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapyHepatology, 2006
- Suicidal ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis CGeneral Hospital Psychiatry, 2004
- Interstitial Pneumonitis in a Patient Treated with α-Interferon and Ribavirin for Hepatitis C InfectionThe American Journal of the Medical Sciences, 2001
- Localized Interferon Alfa-2b-Induced AlopeciaArchives of Dermatology, 1999
- Immune thrombocytopenia and α-interferon therapyJournal of Hepatology, 1996
- A survey of adverse events in 11 241 patients with chronic viral hepatitis treated with alfa interferonJournal of Hepatology, 1996